

Operations Updates as Ms Anne Bell Steps Down as CFO

Melbourne, Australia – 15 September 2021: Adherium Limited (ASX: ADR), a leader in respiratory eHealth, remote monitoring, and data management solutions, announces that Ms Anne Bell has stepped down by mutual agreement from her role as the Chief Financial Officer effective 15 September 2021.

Mr Rick Legleiter, Chief Executive Officer, commented, "I would like to thank Anne on behalf of Adherium and our entire team for her professionalism and contribution. Over the past year Anne helped the company through an important transformational stage and key fund-raising round. I appreciate Anne's support and wish her all the best."

Recruiting Anne's replacement is underway with both interim internal and external bridging support. Going forward the CFO position will be based in Melbourne where Mr Legleiter is establishing the Company's corporate headquarters. Mr Legleiter, added, "It is great to have landed and to be back in Melbourne following my international relocation. As an ASX listed company, I feel it is important to be closer to our investors and the market and to be on the ground leading our Australia and New Zealand based teams developing our next generation products. We are recruiting and staffing positions in Australia and working with our local partner and investor Planet Innovation to offer the products needed to increase sales and generate revenue for the business."

Mr Legleiter continued, "The time before I departed the U.S. was well utilized taking advantage of open travel opportunities in the States during the pandemic meeting firsthand with U.S. partners before my relocation. With those insights I am now better placed to address the strategic, operational and cultural challenges facing our business."

About Adherium (ASX: ADR)

Adherium is a provider of digital health solutions and a global leader in connected respiratory medical devices, with more than 170,000 sold globally. The Company



develops, manufactures and supplies a broad range of connected medical devices for respiratory medications for patients, pharmaceutical companies, healthcare providers and contract research organisations. Adherium's Hailie® solution is designed to help patients achieve better adherence and provide visibility to parents and caregivers. It does this by tracking medication use and reminding the user with helpful nudges when it is time to take doses, and by providing access to usage history to better understand patterns in their Asthma and COPD.

Learn more at www.adherium.com

This ASX announcement was approved and authorised for release by the Board of Adherium.

Enquiries: Rick Legleiter CEO Adherium Limited investors@adherium.com